Interferon (Alpha, Beta and Omega) Receptor 2 Is a Prognostic Biomarker for Lung Cancer | Zendy

Sonosuke Tanaka | Zendy; Noboru Hattori | Zendy; Nobuhisa Ishikawa | Zendy; Yasushi Horimasu | Zendy; Naoko Deguchi | Zendy; Atsushi Takano | Zendy; Yoshitaka Tomoda | Zendy; Koji Yoshioka | Zendy; Kazunori Fujitaka | Zendy; Koji Arihiro | Zendy; Morihito Okada | Zendy; Akihito Yokoyama | Zendy; Nobuoki Kohno | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interferon (Alpha, Beta and Omega) Receptor 2 Is a Prognostic Biomarker for Lung Cancer

Author(s) -

Sonosuke Tanaka,

Noboru Hattori,

Nobuhisa Ishikawa,

Yasushi Horimasu,

Naoko Deguchi,

Atsushi Takano,

Yoshitaka Tomoda,

Koji Yoshioka,

Kazunori Fujitaka,

Koji Arihiro,

Morihito Okada,

Akihito Yokoyama,

Nobuoki Kohno

Publication year - 2012

Publication title -

pathobiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.941

H-Index - 53

eISSN - 1423-0291

pISSN - 1015-2008

DOI - 10.1159/000331230

Subject(s) - lung cancer , medicine , biomarker , lung , immunohistochemistry , cancer , oncology , alpha (finance) , alpha interferon , cancer research , pathology , interferon , biology , immunology , surgery , biochemistry , construct validity , patient satisfaction

It has been reported that the type I interferon receptor subunit, interferon (alpha, beta and omega) receptor 2 (IFNAR2), is overexpressed in several malignancies, primarily adenocarcinomas (ADCs); however, the biological significance of IFNAR2 in human lung cancer has not yet been studied.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research